CervoMed (CRVO) News Today $8.90 +0.37 (+4.34%) Closing price 04:00 PM EasternExtended Trading$9.04 +0.14 (+1.57%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRVO Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period CervoMed Inc. Reports Promising Phase 2b Trial Results for Neflamapimod in Dementia with Lewy BodiesOctober 8 at 7:31 AM | quiverquant.comQCervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy BodiesOctober 8 at 7:00 AM | globenewswire.comCervoMed Appoints Matthew Winton, Ph.D., as Chief Commercial and Business OfficerOctober 7 at 12:42 PM | markets.businessinsider.comShort Interest in CervoMed Inc. (NASDAQ:CRVO) Decreases By 31.7%October 6 at 3:32 AM | marketbeat.comCervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities ConferenceOctober 2, 2025 | globenewswire.comCervoMed Inc. (NASDAQ:CRVO) Given Average Recommendation of "Moderate Buy" by AnalystsSeptember 23, 2025 | marketbeat.comCervoMed announces development program, benefits of neflamapimodSeptember 17, 2025 | msn.comCervoMed Inc. Highlights Promising Neflamapimod Development for Dementia with Lewy Bodies at Annual Neurological ConferenceSeptember 17, 2025 | quiverquant.comQCervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association ConferenceSeptember 17, 2025 | globenewswire.comWhat is HC Wainwright's Estimate for CervoMed Q3 Earnings?September 13, 2025 | marketbeat.comHC Wainwright Reiterates Neutral Rating for CervoMed (NASDAQ:CRVO)September 10, 2025 | marketbeat.comH.C. Wainwright sets CervoMed price target into FDA claritySeptember 9, 2025 | msn.comCervoMed Gets $11 Price Target From HC Wainwright, Analyst Says Regulatory Outlook For Experimental Dementia Drug Should Be Clear SoonSeptember 9, 2025 | msn.comNuveen LLC Takes $312,000 Position in CervoMed Inc. $CRVOSeptember 8, 2025 | marketbeat.comAWM Investment Company Inc. Acquires New Shares in CervoMed Inc. $CRVOSeptember 5, 2025 | marketbeat.comShort Interest in CervoMed Inc. (NASDAQ:CRVO) Drops By 54.5%September 5, 2025 | marketbeat.comCervoMed Inc. to Present at Upcoming Investor Conferences in September 2025September 3, 2025 | quiverquant.comQCervoMed to Participate in Upcoming Investor ConferencesSeptember 3, 2025 | globenewswire.comCervoMed Inc. (NASDAQ:CRVO) Receives Average Rating of "Moderate Buy" from AnalystsAugust 31, 2025 | marketbeat.comBrookline Capital Management Predicts CervoMed Q3 EarningsAugust 22, 2025 | marketbeat.comD. Boral Capital Increases CervoMed (NASDAQ:CRVO) Price Target to $31.00August 20, 2025 | marketbeat.comCervoMed price target raised to $31 from $15 at D. Boral CapitalAugust 18, 2025 | msn.comShort Interest in CervoMed Inc. (NASDAQ:CRVO) Expands By 563.1%August 16, 2025 | marketbeat.comChardan Capital Predicts Stronger Earnings for CervoMedAugust 16, 2025 | marketbeat.comRoth Capital Has Bearish Estimate for CervoMed Q3 EarningsAugust 16, 2025 | marketbeat.comCervoMed Reports Promising Trial Results and Financial UpdateAugust 12, 2025 | msn.comCervoMed price target lowered to $16 from $20 at Roth CapitalAugust 12, 2025 | msn.comCervoMed (NASDAQ:CRVO) Price Target Raised to $15.00August 12, 2025 | marketbeat.comChardan Capital Reaffirms "Buy" Rating for CervoMed (NASDAQ:CRVO)August 12, 2025 | marketbeat.comCervoMed Reports Second Quarter 2025 Financial Results and Provides Corporate UpdatesAugust 12, 2025 | finance.yahoo.comCervoMed (NASDAQ:CRVO) Announces Earnings Results, Misses Expectations By $0.13 EPSAugust 11, 2025 | marketbeat.comCitizens Financial Group Inc. RI Buys New Position in CervoMed Inc. (NASDAQ:CRVO)August 11, 2025 | marketbeat.comAvantax Advisory Services Inc. Makes New $238,000 Investment in CervoMed Inc. (NASDAQ:CRVO)August 11, 2025 | marketbeat.comCervoMed Shares Business and Financial Updates OnlineAugust 5, 2025 | tipranks.comCervoMed to Participate in the Canaccord Genuity 45th Annual Growth ConferenceAugust 5, 2025 | finance.yahoo.comCervoMed Inc. (NASDAQ:CRVO) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesAugust 4, 2025 | marketbeat.comCervoMed (CRVO) Projected to Post Earnings on FridayAugust 1, 2025 | marketbeat.comCanaccord Genuity Group Issues Positive Forecast for CervoMed (NASDAQ:CRVO) Stock PriceJuly 30, 2025 | marketbeat.comCervoMed stock soars after positive dementia drug trial dataJuly 29, 2025 | za.investing.comCervoMed Dementia Drug Slows Disease Progression In Study: Retail Loads Up On The StockJuly 29, 2025 | msn.comCervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod's Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of NeurodegenerationJuly 28, 2025 | globenewswire.comCervoMed's (CRVO) Buy Rating Reiterated at D. Boral CapitalJuly 26, 2025 | marketbeat.comCervoMed Q2 2025 Earnings PreviewJuly 25, 2025 | msn.comCervoMed Inc. (NASDAQ:CRVO) Given Average Recommendation of "Moderate Buy" by BrokeragesJuly 10, 2025 | marketbeat.comCervoMed Strengthens Leadership with Technical Operations Hire to Advance Neflamapimod Toward Phase 3July 9, 2025 | finance.yahoo.comCervoMed Announces Late-Breaking Presentations at Alzheimer’s Association® International Congress 2025July 8, 2025 | finance.yahoo.comCervoMed Announces Late-Breaking Presentations at Alzheimer's Association® International Congress 2025July 8, 2025 | globenewswire.comCervoMed Inc. (NASDAQ:CRVO) Shares Sold by Perigon Wealth Management LLCJuly 2, 2025 | marketbeat.comCervoMed Inc. (NASDAQ:CRVO) Receives Average Recommendation of "Moderate Buy" from AnalystsJune 15, 2025 | marketbeat.comCervoMed Inc. (NASDAQ:CRVO) Sees Significant Decrease in Short InterestJune 13, 2025 | marketbeat.com Get CervoMed News Delivered to You Automatically Sign up to receive the latest news and ratings for CRVO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CRVO Media Mentions By Week CRVO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRVO News Sentiment▼0.780.60▲Average Medical News Sentiment CRVO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRVO Articles This Week▼53▲CRVO Articles Average Week Get the Latest News and Ratings for CRVO and Related Stocks Enter your email address to receive the latest news and analysts' ratings for CervoMed and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies CADL News ALDX News SCPH News GALT News EDIT News AARD News ACIU News TECX News IMAB News NMRA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRVO) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredThe 'Big Beautiful Bill' That Could Break AmericaOn July 4th, they celebrated the $3.4 trillion "One Big Beautiful Bill Act." What they didn't say? This bil...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CervoMed Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CervoMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
